Table 2

Disproportionality analysis by drug

DrugROR95% CI (p<0.001)% GBS over other events
Avelumab29.85414.8 to 58.90.57
Atezolizumab17.07512.5 to 23.10.32
Ipilimumab16.08412.4 to 20.80.30
Pembrolizumab11.9779.4 to 15.10.22
Nivolumab8.2186.3 to 10.60.15
  • .GBS, Guillain-Barré syndrome; ROR, reporting OR.